10 2 月, 2026 – 第 2 頁

ACN Newswire

Mint Signed MoU with Robotics Leader Rice Robotics to Pioneer Physical AI Solutions Across Asia

February 9, 2026

HONG KONG, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) – Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Aspiration X Limited (“Aspiration X”), has signed a non-binding Memorandum of Understanding (“MOU”) to explore the formation of a strategic joint venture with a renowned delivery robotics company, Rice Robotics Holdings Limited (“Rice Robotics”). Under the MOU, both parties intend to establish a joint venture with an initial investment of approximately HK$10,000,000 to be funded by Mint, subject to the negotiation and execution of definitive agreements. The proposed collaboration centers on a shared goal of developing localized robotic technologies and expanding related research and development (“R&D”) capabilities in Hong Kong.At its core, the proposed joint venture aims to accelerate the development and deployment of intelligent robotic solutions. Mint brings its established footprint in Southeast Asia—including smart office solutions in Singapore and security robot deployments in Thailand and Malaysia—while Rice Robotics contributes its expertise in delivery robots and a robust presence in Japan, serving prestigious clients. The parties intend to leverage their respective strengths in terms of R&D, marketing, and branding to achieve expansive market coverage. Commenting on the strategic initiative, Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint stated: “This partnership provides a compelling response to the question, ‘Why not Hong Kong'’ While the city is renowned for fintech and finance, we believe it has the talent and vision to be a leader in physical AI and robotics innovation. Many local firms act mainly as sales channels, but together with Rice Robotics, we are building core proprietary technology here. We were impressed by Rice Robotics’ proven delivery robotics platform and its network of high-profile clients in Japan. This partnership significantly diversifies and strengthens our robotics portfolio, allowing us to move beyond B2B into the promising B2C space—developing robots for companionship, education, and daily life, powered by our robust AI.”Mr. Victor Lee, Founder of Rice Robotics, added: “Mint’s rapid expansion in AI and robotics across Southeast Asia makes it an ideal partner. Its dedicated commercial teams and AI platform will dramatically accelerate our joint R&D and market expansion. We share a bold vision to build the most anticipated robotics company in Hong Kong and drive meaningful diversification in the region’s tech ecosystem. This joint venture will serve as a strategic accelerator for both companies.”The collaboration is strategically timed to capitalize on the transformative shift towards "Physical AI"—systems capable of reasoning, planning, and acting autonomously in the real world. By combining Rice Robotics’ proven robotics hardware and market expertise with Mint’s advanced AI platform, the joint venture will occupy a unique position at the forefront of this revolution. Both partners are committed to developing smarter, more intuitive robotic solutions that address real-world challenges, enhance everyday life, and set the stage for the next generation of autonomous technology.The MOU is non-binding and subject to the execution of definitive agreements and satisfaction of customary conditions.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Aspiration X, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.Rice Robotics Holdings LimitedRice Robotics Holdings Limited is a renowned leader in autonomous delivery robot solutions, with a strong market presence across Asia. The company specializes in the design, development, and deployment of intelligent robotic systems for logistics and service industries. Its core technology platforms serve high-profile clients in Japan, demonstrating proven reliability in complex operational environments. With a focus on innovation and real-world application, Rice Robotics is committed to transforming last-mile delivery and service automation, enhancing operational efficiency and redefining customer experiences.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company's filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JCN Newswire

KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System

February 9, 2026

TOKYO, Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - KS Energy Co., Ltd. ("KS Energy"), a renewable energy business company and Hitachi, Ltd. (TSE:6501, “Hitachi”) agreed on February 6 to collaborate on the development and operation of an Extra-High Voltage Grid Battery Energy Storage System*1 within Kumamoto Prefecture, as well as the development and operation of power trading businesses. Hitachi will provide project development support for KS Energy's development of the project and jointly promote the development and operation of this battery energy storage system (tentative name)*2 . Additionally, KS Energy will also explore the introduction of a power trading support system planned for development by Hitachi.This initiative will support stable power supply in the Kyushu region and contribute to achieving carbon neutrality.*1 Extra-High Voltage Grid Battery Energy Storage System: Large-scale battery storage facilities directly connected to the power grid (such as transmission lines) with a capacity of 2,000 kW or more.*2 Power Trading Support System: A power trading support system for operators managing large-scale grid-connected storage batteries. It supports traders' daily operations comprehensively—from bid planning and market transactions to submitting plans to OCCTO—across both the supply-demand adjustment market and the wholesale electricity market. System development also incorporates collaboration with other companies, such as bid plan optimization services. This contributes to improved profitability through trading based on optimal bid plans and streamlines routine daily tasks like plan submission.BackgroundRenewable energy generation fluctuates due to weather changes and other factors, significantly impacting the power supply-demand balance. Particularly in the Kyushu region, where renewable energy adoption is advancing, output curtailment occurs frequently when generation exceeds demand. Securing balancing power to stabilize the power grid is an urgent priority. Furthermore, as the policy framework for promoting renewable energy shifts from the FIT (Feed-in Tariff) system to the FIP (Feed-in Premium) system, power generators are now required to develop their own electricity trading capabilities to formulate strategies for selling electricity in the power market. Against this backdrop, the importance of "aggregators" – entities that consolidate and control energy resources to adjust supply-demand balance – is growing. They are expected to contribute to the effective utilization and stable supply of renewable energy by engaging in both the electricity market and the power trading market.To address this situation, KS Energy, established in January 2024 with full investment from Higo Bank, Ltd. (part of the Kyushu Financial Group), has adopted a policy to contribute to stabilizing power supply as a regional energy company, aiming to make the entire Kyushu region a leading area for renewable energy circulation. Meanwhile, Hitachi has a long history in the power sector, providing a wide range of advanced solutions from energy storage systems to transmission and distribution infrastructure and grid protection devices.Through this collaborative effort, both companies will combine their respective strengths. By developing and operating energy storage facilities and engaging in power trading, they aim to achieve carbon neutrality in the Kyushu region.Initiative DetailsKS Energy and Hitachi have decided to jointly develop and operate battery energy storage system in the Kyushu region. This initiative contributes to stabilizing local power supply by charging and discharging in response to electricity demand-supply balance, thereby providing balancing power.1. Nation's First Extra-High Voltage Battery Energy Storage System project launched by a regional bank group This marks the first instance nationwide of a bank subsidiary's renewable energy business company undertaking a grid energy battery business in the extra-high voltage range. Through this initiative, we aim to contribute to stable power supply. Additionally, KS Energy is considering managing the power trading for the storage facility in-house. The plan involves handling the entire operational process: forecasting electricity market prices, creating power generation (charging/discharging) plans for the batteries, controlling the storage facility, and monetizing through market transactions. In the future, leveraging its operational expertise in storage facilities and collaborating with Higo Bank, KS Energy will enhance support for power generators and provide financing support to storage facility developers. This will enable the delivery of services extending beyond the financial sector, promote efficient electricity usage within local communities, and contribute to achieving regional carbon neutrality and decarbonization.2. Joint Promotion of Project Development from the Early Stage Leveraging Hitachi’s extensive experience in battery energy storage systems, Hitachi and KS Energy will jointly promote the development of energy storage facilities. The Hitachi Group will work together to promote project development through to operational launch. This includes cooperation from grid connection application discussions with transmission and distribution operators to applications and procedures with relevant ministries and agencies, provision of business feasibility evaluation information, supply of Hitachi Energy-manufactured PCS, and project management covering equipment design, procurement, and installation. Hitachi will sustainably support KS Energy's stable operations of the storage facility.3. Collaboration in Power Trading Business To stably utilize rapidly expanding renewable energy, the need for aggregation functions that balance electricity supply and demand is growing. KS Energy is considering introducing Hitachi's planned power trading support systemto achieve efficient energy resource utilization and aim for stable power supply. Under Hitachi's Lumada 3.0 initiative, the company is deploying "HMAX by Hitachi" (hereinafter HMAX), a next-generation AI solution suite that tackles the most complex challenges facing social infrastructure. This is achieved by combining vast data from both physical and digital assets with advanced AI enhanced by Hitachi's unique deep domain knowledge. In the electric power trading area as well, Hitachi will realize services that optimize the operation of storage battery assets and maximize market value, and aim to deploy them as HMAX.Future DevelopmentsKS Energy and Hitachi will collaborate to achieve both the mainstreaming of renewable energy as a primary power source and stable supply through the development of battery energy storage system and enhanced aggregation functions, working together toward realizing regional carbon neutrality.Overview of Grid-Connected Storage FacilityStorage Facility Name : (Provisional name) KSE Kumamoto Battery Energy Storage SystemStorage Facility Location (Planned) : Within Kumamoto PrefectureRated Output/Rated Capacity (Planned) : 50,000 kW / 112,880 kWhScheduled Start of Operation : January 2029 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

JCN Newswire

Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

February 9, 2026

TOKYO and CAMBRIDGE, Mass., Feb 10, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China.The Priority Review and Approval Procedure was implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250 mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population. LEQEMBI was launched in China in June 2024 and has been delivered in the private market. Furthermore, LEQEMBI has been included in the newly introduced “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, Commercial insurance companies will develop insurance products covering LEQEMBI.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In China, Eisai will distribute the product and conduct information provision activities through specialized Medical Representatives.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.com About LEQEMBI (generic name: lecanemab, Chinese brand name: 乐意保)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 7 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more information, visit https://www.eisai.com/news/2026/pdf/enews202608pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

SeaPRwire

Dr. Don Hits Seven-Figure Milestones on Three Music Videos in Less than a Year

February 9, 2026

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape. According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge. Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.” The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time. Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music. Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone. This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates. About Dr. Don Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression. Media Contact Dr. Don E: don@drdonmusic.com W: https://drdonmusic.com/

ACN Newswire

Spritzer EcoPark Gallops into the Year of the Horse with a Tradition-Inspired Chinese New Year Celebration

February 9, 2026

Festive decorations transform the park into a mesmerising cultural experience, celebrating prosperity, renewal and togethernessTAIPING, Malaysia, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) - This Chinese New Year, Spritzer EcoPark invites all Malaysians to join in on the energy and excitement in welcoming the Year of the Fire Horse! Set against the vibrant and verdant backdrop of where tradition meets nature in Malaysia’s rainiest town of Taiping, Spritzer EcoPark continues their annual tradition to inspire and promote togetherness, reflection, and fresh beginnings.From this February to early March 2026, Spritzer EcoPark comes alive as a Chinese New Year cultural village, offering visitors an immersive walk-through experience designed to reflect prosperity, good fortune and new beginnings. In the same spirit, admission is free to ensure the Spritzer EcoPark remains an accessible destination for families and visitors of all ages.In Chinese culture, the Horse symbolises vitality, perseverance, freedom, and forward momentum, which are qualities closely associated with breakthroughs and stepping boldly into new opportunities. As the zodiac cycle moves from the reflective, introspective energy of the Year of the Snake, the dynamic Year of the Horse is expected to usher in a shift towards confident action.Figure 1: One of the many horse-themed Chinese New Year outdoor decorations at Spritzer EcoPark.Drawing inspiration from this symbolism, Spritzer EcoPark’s festive transformation aims to capture the essence of the New Year and zodiac, encouraging visitors to step into the year with optimism, courage, and a renewed spirit. Thoughtfully curated decorations weave traditional Chinese New Year elements into the park’s lush natural surroundings. Festive arches, pavilion-inspired structures, glowing red lanterns, cherry blossoms, auspicious symbols, Horse and zodiac motifs/decor, and interactive display zones turn the park into a charming, photo-worthy landscape, perfect for capturing meaningful memories with family and friends while enjoying the festive atmosphere.As one of Taiping’s must-visit destinations for locals and tourists alike, Spritzer EcoPark offers a range of engaging activities suitable for visitors of all ages. Families can enjoy in DIY & Crafting sessions, try their hand at Mini Golf with LED Golf Balls and take part in a friendly race on the Paddle Carts amidst the fresh Taiping air, all available at affordable prices. For visitors looking to slow down amidst the festivities, STG Taiping café offers a cozy and relaxing spot to unwind and recharge with refreshing drinks and snacks. Those who do not want to go home empty-handed can also stop by the Spritzer Water Shop to stock up on Spritzer beverages for festive gatherings or explore the exclusive souvenirs and seasonal promotions at the Souvenir Shop.Figure 2 and 3: Spritzer EcoPark's decorations are thoughtfully curated to weave traditional Chinese New Year elements into the park’s lush natural surroundings.More than a seasonal attraction, Spritzer EcoPark reflects the brand’s commitment to wellness, creativity, sustainability and meaningful shared experiences. Surrounded by nature and guided by Spritzer’s values, the EcoPark provides a relaxing space for visitors to slow down, reconnect with loved ones and celebrate the simple joys of the season.Winnie Chin, Head of Public Relations at Spritzer said, “Each year, Spritzer strives to create fresh and memorable experiences for our visitors. The Year of the Horse represents progress and vitality, and we want this celebration to reflect those qualities through an immersive environment that brings families together in these natural surroundings. Our goal is to offer a space where people can relax, reconnect, stay hydrated and begin the new year feeling refreshed and inspired.”Spritzer EcoPark extends its warmest wishes for a Happy Chinese New Year. May the Year of the Fire Horse bring prosperity, wellness, and joy for all.The park is open daily from 10:00 AM to 9:30 PM and is located at Lot 898, Jalan Reservoir, Off Jalan Air Kuning, 34000 Taiping, Perak.For the latest news and updates, follow Spritzer EcoPark on Facebook and Instagram. For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Fangzhou 的「XingShi」大型語言模型獲選為中國2026年最受期待的醫療保健模型之一

February 9, 2026

(SeaPRwire) - 上海，2026年2月10日 -- 行業研究平台VBData近日將Fangzhou Inc.（「Fangzhou」或「本公司」）（HKEX: 06086）的「星石」大型語言模型（「XS LLM」）評為中國2026年最受期待的醫療保健AI模型之一。Fangzhou Inc.是AI驅動的互聯網醫療保健解決方案的領導者。「星石」大型語言模型（「XS LLM」）將知識服務、分診、預問診、醫生支持和電子病歷五個智能代理整合到一個涵蓋整個慢性病管理週期的閉環系統中，這種方法已引起國際關注，包括Nature的報導。作為與OpenEvidence的出現同步開發的最早的國內模型之一，XS LLM由來自Chinese Medical Association數據庫中170多種核心期刊的110多萬篇文章提供支持，涵蓋所有主要臨床學科。VBData估計該模型已為醫生提供了近40萬次技術協助，使其成為臨床支持和專業工作流程的重要工具。作為Fangzhou平台「核心數字大腦」而構建的XS LLM，為五個AI賦能應用提供支持：AI Medication Finder、AI Health Manager、AI Doctor Assistant、AI Academic Assistant和AI-Powered Search。每個產品都解決了不同的臨床和患者端用例，實現了在用藥指導、患者教育、診斷協助和醫療參考方面的實時精準干預。 XS LLM此前曾被Nature 新聞版塊報導，標題為「A Chinese AI tool can manage chronic disease — could it revolutionize health care?」，該文章探討了該模型的發展，以及專家對其改善慢性病管理的潛在影響的看法。 VBData引用的其他模型包括來自JD Health、Ant Group和Tencent Health的產品。VBData指出，領先的國內醫療AI模型正日益針對中國特有的臨床指南、報銷框架和監管要求進行優化，以實現到2027年醫療AI模型廣泛發展和到2030年基層醫療近乎普及的智能臨床協助的宏偉國家目標。展望未來，Fangzhou將繼續深化AI在慢性病服務中的整合，並擴大專業、技術賦能護理的可及性，同時鞏固其在國家醫療保健數字化進程中的關鍵參與者地位。關於VBDataVBData成立於2014年，是一個行業信息加速器平台，通過深度分析建立商業案例庫，通過系統研究解構行業，並通過專屬服務促進產業合作。關於Fangzhou Inc.Fangzhou Inc. (HKEX: 06086)是中國領先的在線慢性病管理平台，服務於5280萬註冊用戶和22.9萬名醫生（截至2025年6月30日）。本公司專注於提供量身定制的醫療護理和AI賦能的精準醫療解決方案。欲了解更多信息，請訪問。媒體聯繫如需進一步查詢或採訪，請聯繫：Xingwei Zhao 公共關係副總監電郵：pr@jianke.com 免責聲明：本新聞稿包含前瞻性陳述。實際結果可能因各種因素而與預期存在重大差異。讀者應注意不要過度依賴這些陳述。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

ACN Newswire

鈞達股份(002865.SZ/02865.HK)雙賽道卡位控股巡天千河打通太空能源-衛星閉環

February 9, 2026

香港, 2026年2月10日 - (亞太商訊 via SeaPRwire.com) - 2月8日，招商證券發佈研報指出，上海復遙星河航天科技有限公司發生工商變更，鈞達股份(002865.SZ/02865.HK)以60%持股比例成為其控股股東，而復遙星河航天科技100%持股商業衛星公司巡天千河，這意味著鈞達股份正式實現對巡天千河的間接控股。作為國內知名的衛星整星公司，巡天千河的核心競爭力成為鈞達股份此次佈局的重要價值錨點。研報顯示，巡天千河技術團隊源於航天科技集團，擁有近百顆商業衛星研製經驗，團隊配置堪稱行業頂尖，包含6名博士、11名碩士，平均年齡35歲以下，全部核心分系統負責人，均由核心院所主任/副主任設計師擔任。在技術與產能方面，該公司掌握衛星核心單機、有效載荷核心技術，供應鏈自研比例約70%，可提供衛星研製、新技術搭載驗證、用戶終端研製等一體化解決方案，整星製造能力覆蓋10kg至1000kg各類衛星，應用領域涵蓋通信、遙感、態勢感知、AI算力等多領域。從商業化進展來看，巡天千河已形成成熟的项目落地能力，2024年以來已成功發射近10顆衛星，同時承接了近30餘顆商業衛星研製任務，其新體制光學遙感一體化衛星研製水準達國際一流，微波氣象載荷平台一體化衛星技術更是處於國內領先地位，是國內稀缺的同時具備被動微波載荷、物聯網載荷、光學感知載荷能力的企業，具備平台一體化柔性定制化批產能力，為後續業務拓展奠定了堅實基礎。據悉，目前巡天千河研發總部已遷至上海松江，恰逢上海全力打造商業航天產業集群並出台多項扶持政策，包括項目固定資產投資補貼、衛星發射與保險補貼、航天器入軌運營獎勵等，巡天千河有望直接享受產業與政策紅利。研報同時披露，巡天千河已制定四大發展戰略，將持續夯實遙感衛星市場、佈局通訊衛星市場、開拓算力衛星新賽道，並大力拓展海外市場。此次控股並非鈞達股份的孤立佈局，而是其太空領域戰略的重要一環，且與公司現有業務形成深度協同。研報指出，鈞達股份作為首家A+H上市光伏主產業鏈公司，資本實力雄厚且擁有靈活的激勵機制，能為巡天千河提供充足財力保障；更關鍵的是，鈞達股份在CPI膜、鈣鈦礦&晶矽領域有望與巡天千河的衛星業務形成天然適配，其太空能源產品可直接對接巡天千河的衛星能源需求，實現技術與應用場景的閉環。 2026年1月，公司與尚翼光電/上海光機所深度合作，不僅持有尚翼光電團隊創始人及創始股東新設的項目公司星翼芯能16.67%的股份，成為其第二大股東，還與其成立了鈞達航天空間科技（均達持股70%，星翼芯能持股30%），專門負責CPI膜和鈣鈦礦疊層產品的產業化。該合資公司在太空能源應用領域有較深積累，有望快速進入國內外大客戶體系。招商證券認為，此次控股巡天千河，讓鈞達股份實現了「太空能源（鈣鈦礦晶矽疊層、CPI膜）+衛星整星製造」的產業鏈佈局，形成技術研發、產品製造、場景應用的閉環，兩大業務板塊將形成協同共振，核心競爭力進一步凸顯。2026年2月2日，鈞達股份還完成了H股配售，募資淨額約4億港元，將重點投入商業航天相關領域。整體來看，鈞達股份此前成功卡位太空光伏賽道，此次控股巡天千河又讓其進一步切入衛星領域，商業航天技術和A+H雙平台的資本優勢結合，有望推動公司實現跨越式發展。（本文數據均來自招商證券研報，不構成任何投資建議） Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Neo-Concept International Group Holdings Limited 公佈約 810 萬美元 A 類普通股公開發售定價

February 9, 2026

(SeaPRwire) - 香港，2026年2月9日 -- 一站式服裝解決方案服務供應商 Neo-Concept International Group Holdings Limited (Nasdaq: NCI)（下稱「本公司」）今日宣布，於2026年2月9日訂定其公開發行（下稱「是次發行」）的定價，以每股A類普通股0.5454美元的公開發行價發行14,850,000股A類普通股。在扣除配售代理費及其他發行費用前，是次發行的總集資額預計約為810萬美元。是次發行預計將於2025年2月11日完成，惟須滿足慣常交割條件。本公司擬將是次發行的所得款項淨額用於擴展其業務及作為一般營運資金。 D. Boral Capital LLC 擔任是次發行的主配售代理，而 uSmart Securities Limited 則擔任聯合配售代理（與 D. Boral Capital LLC 合稱「配售代理」）。Loeb & Loeb LLP 擔任本公司的美國法律顧問，而 Mclaughlin & Stern, LLP 則擔任是次發行中配售代理的法律顧問。上述證券是根據經修訂的F-1表格登記聲明（檔案編號：333-288993）（下稱「登記聲明」）進行發售，該登記聲明已於2025年2月9日獲美國證券交易委員會（下稱「SEC」）宣布生效。是次發行僅透過屬於登記聲明一部分的招股章程進行。在投資前，您應閱讀招股章程及本公司已向或將向SEC提交的其他文件，以獲取有關本公司及是次發行的更多資訊。您可以透過訪問SEC網站上的EDGAR數據庫免費獲取這些文件。最終招股章程的電子副本（如有）可向 D. Boral Capital LLC 索取，或致電 +1 (212) 970-5150。本新聞稿僅供參考，並不構成出售要約或徵求購買任何證券的要約，且在任何州或司法管轄區內，在根據該州或其他司法管轄區的證券法例進行登記或資格審定之前，不得進行此類要約、徵求或銷售。前瞻性陳述本公告中的某些陳述屬於前瞻性陳述。這些前瞻性陳述涉及已知和未知的風險及不確定性，並基於本公司對其認為可能影響其財務狀況、經營業績、業務策略及財務需求的未來事件的當前預期和預測。投資者可透過「可能」、「將會」、「預期」、「目標」、「估計」、「打算」、「計劃」、「相信」、「有可能」、「潛在」、「繼續」或其他類似表述來識別這些前瞻性陳述。除法律可能要求外，本公司無義務公開更新或修訂任何前瞻性陳述以反映後續發生的事件或情況，或其預期的變化。儘管本公司相信這些前瞻性陳述中表達的預期是合理的，但無法向您保證這些預期最終會是正確的，本公司提醒投資者實際結果可能與預期結果存在重大差異，並鼓勵投資者查閱可能影響其未來業績的其他因素，詳見本公司向SEC提交的登記聲明及其他文件，該等文件可在查閱。關於 Neo-Concept International Group Holdings Limited Neo-Concept International Group Holdings Limited（「NCI」）是一站式服裝解決方案服務供應商。它提供服裝供應鏈的全套服務，包括市場趨勢分析、產品設計與開發、原材料採購、生產與質量控制，以及物流管理，服務位於歐洲和北美市場的客戶。它還通過其在英國和阿聯酋的零售店以及電子商務平台，以「Les100Ciels」品牌銷售自有品牌的服裝產品。 NCI 致力於透過實施各種環保實踐來最小化其環境足跡。它將回收、清潔生產和可追溯採購作為其減少環境影響承諾的一部分。此外，NCI 在整個服裝生產過程中積極尋求可持續的解決方案，旨在以對環境負責的方式滿足客戶的需求。欲了解更多信息，請訪問本公司網站。查詢請聯絡： Neo-Concept International Group Holdings Limited 香港九龍觀塘海濱道139-141號海濱中心10樓(+852) 2798-8639電郵：本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

News

特朗普威脅要封鎖通往加拿大的橋梁

February 9, 2026

(SeaPRwire) - 美國總統要求獲得安大略省與密歇根州之間跨境通道「至少一半」的所有權總統唐納德·特朗普（Donald Trump）威脅稱，除非華盛頓獲得補償並持有該項目部分股權，否則將阻止連接加拿大與美國的一座大型新橋樑通車。特朗普周一在其Truth Social平台上發表長文稱，除非美國獲得「充分補償」，且加拿大以他所謂的「公平與尊重」對待美國，否則他不會允許連接安大略省溫莎市與密歇根州底特律市的戈迪·豪國際大橋（Gordie Howe International Bridge）通車。「鑒於我們給予他們的一切，我們或應擁有這項資產至少一半的所有權。因美國市場產生的收入將是天文數字，」他寫道。特朗普指責加拿大從該項目中獲益過多，聲稱該項目「幾乎沒有美國成分」，並指控前總統巴拉克·奧巴馬（Barack Obama）時期頒發的豁免允許加拿大規避「購買美國貨」（Buy American）要求。他還再次提及長期以來的不滿，包括加拿大的乳製品關稅、各省對美國酒精銷售的限制，以及渥太華與中國的接觸。特朗普在其第一任期內支持該橋樑，稱其為「至關重要的經濟紐帶」，儘管大使橋（Ambassador Bridge）的所有者長期以來反對該項目並進行了遊說。這一新威脅出現之際，美加關係正面臨更廣泛的緊張局勢。近幾週，特朗普還警告將對加拿大製造的飛機徵收高額關稅，並暗示若渥太華加深與北京的貿易關係，將採取懲罰性措施。加拿大總理馬克·卡尼（Mark Carney）否認了加拿大正在尋求與中國簽署自由貿易協定的說法，並敦促華盛頓尊重加拿大的主權。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

ACN Newswire

Mint與領先機械人公司Rice Robotics簽署合作備忘錄共同開拓亞洲實體人工智慧解決方案

February 9, 2026

香港, 2026年2月10日 - (亞太商訊 via SeaPRwire.com) - Mint Incorporation Limited（「Mint」或「集團」，納斯達克股票代碼：MIMI），一家專注於人工智能與機械人技術，同時提供商業室內設計及裝修服務的香港本土企業，今日欣然宣布，其全資子公司Aspiration X Limited（「Aspiration X」）與知名配送機械人公司Rice Robotics Holdings Limited（「Rice Robotics」）簽署非約束性合作備忘錄以探索成立戰略合資企業。由Mint提供資金，雙方計劃初步投資約HK$10,000,000成立一家合資企業，具體將按最終協議的協商和簽署而定。擬議的合作旨在共同發展本土化的機器人技術，並拓展香港相關研發能力。是次提議的合資企業旨在加速智能機械人解決方案的開發與部署。Mint將發揮其在東南亞市場的既有優勢 ─ 包括在新加坡的智能辦公室解決方案，以及在泰國和馬來西亞的安防機械人部署；而Rice Robotics則憑藉其在配送機械人領域的專業經驗，以及在日本市場服務知名客戶的穩固佈局，為合作注入動力。雙方將充分利用各自在研發、市場營銷與品牌的優勢實現廣泛的市場覆蓋。Mint董事會主席兼行政總裁陳海龍先生對此戰略舉措表示：「是次合作是對『何以不選擇香港呢？』這問題的有力回應。儘管香港以金融科技與金融服務聞名，我們堅信這座城市擁有引領實體人工智能與機械人創新的人才與視野。許多本地企業主要扮演銷售渠道角色，但我們與Rice Robotics正共同在此構建核心專有技術。Rice Robotics成熟的配送機械人平台及其在日本的高端客戶網絡令人印象深刻。此合作將顯著豐富並強化我們的機械人業務版圖，推動我們從企業級市場拓展至前景廣闊的消費級領域 — 憑藉我們強大的人工智能技術，開發面向陪伴、教育與日常生活的機械人。」Rice Robotics創辦人李國康先生補充道：「Mint於東南亞人工智能與機械人領域的快速擴張，使其成為理想的合作夥伴。其專業商業團隊與人工智能平台將極大加速雙方聯合研發與市場拓展。我們抱有共同願景，立志打造香港最受觸目的機械人企業，推動本地科技生態實現實質性多元發展。此次成立合資企業將顯著提升雙方的市場實力。」此次合作適逢產業邁向「實體人工智能」轉型的關鍵時刻 — 該技術指在能於現實世界中自主推理、規劃與行動的系統。透過融合Rice Robotics成熟的機械人硬件及市場經驗與Mint先進的人工智能平台，是次戰略協議將於此變革確立其關鍵定位。雙方將共同開發更智能、更直觀的機械人解決方案，以應對現實挑戰、提升日常生活品質，並定義新一代自主技術範式。該合作備忘錄是非約束性的，需簽署明確協議並滿足慣例條件。有關Mint Incorporation LimitedMint Incorporation Limited（納斯達克股票代碼：MIMI）是一家於納斯達克上市的香港本土企業，專注於人工智能、機械人技術及室內設計領域。透過其子公司 Aspiration X Limited，公司為企業、地產、商場、政府機構等提供智能機械人與設施管理解決方案。Mint 同時營運 Matter International Limited，提供專業室內設計與裝修服務。秉持創新與實際應用並重的理念，Mint 致力於提升各行各業的效率、安全性與生活質素。有關Rice Robotics Holdings LimitedRice Robotics Holdings Limited 是亞洲市場領先的自動配送機械人解決方案供應商，在區內具有顯著的市場影響力。公司專注於為物流與服務行業設計、開發及部署智能機械人系統。其核心技術平台服務於日本多家知名客戶，在複雜營運環境中展現出卓越的可靠性。Rice Robotics 致力於推動最後一哩配送與服務自動化轉型，透過創新與實際應用提升營運效率，重塑用戶體驗。前瞻性陳述本新聞稿中的某些陳述屬於前瞻性陳述。這些前瞻性陳述涉及已知和未知的風險和不確定性，並基於公司對可能影響其財務狀況、營運成果、業務策略和財務需求的未來事件的目前期望和預測。投資者可通過「大約」、「相信」、「希望」、「期望」、「預期」、「估計」、「項目」、「打算」、「計劃」、「將」、「將會」、「應該」、「可能」或其他類似的詞語或短語識別這些前瞻性陳述。公司不承擔更新或修訂任何前瞻性陳述以反映隨後發生的事件或情況，或其期望的變化的公開義務，除非法律要求。儘管公司認為這些前瞻性陳述所表達的期望是合理的，但無法保證這些期望將會被證實正確，並提醒投資者實際結果可能與預期結果有顯著差異，並鼓勵投資者查閱可能影響其未來結果的其他因素，這些因素披露在公司向證券交易委員會提交的文件中。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

EpimAb Biotherapeutics 宣布其授權合作夥伴 Almirall 完成首個 FIT-IG® 雙特異性抗體的 CTA 申請

February 9, 2026

(SeaPRwire) - 上海，2026年2月10日 -- EpimAb Biotherapeutics，一家專注於開發新型多特異性抗體的臨床階段生物製藥公司，今日宣布其授權合作夥伴Almirall (www.almirall.com) 已根據雙方於2023年達成的授權協議，完成了首次臨床試驗申請 (CTA) 的提交。根據協議條款，Almirall 獲得了 EpimAb 專有的 Fabs-In-Tandem Immunoglobulin (FIT-Ig) 平台技術的授權，用於生成、開發和商業化最多三個未披露的目標配對的雙特異性抗體。根據此授權，首個進入臨床研究的候選藥物將是一種同時靶向 IL-13 和 OX-40L 的雙特異性抗體，用於治療特應性皮炎。Almirall 預計將於2026年上半年啟動其首次人體臨床試驗 (Phase 1)。 EpimAb 的執行長兼創始人 Dr. Chengbin Wu 表示：「以 EpimAb 的技術為基礎，我們的合作夥伴 Almirall 成功地將其首個雙特異性候選藥物推進到臨床開發階段，這對 EpimAb 來說是一個決定性的時刻，因為我們正尋求將我們的 FIT-Ig 技術應用於另一個疾病領域。我們在 EpimAb 資產和平台上的多項合作持續交付重要的臨床前和臨床里程碑，證明了我們內部衍生技術的強大和多功能性。」 FIT-Ig 是 EpimAb 的專有技術平台，僅利用單株抗體的基礎結構部分即可生成雙特異性抗體，而無需添加任何複雜的變更，並已在全球主要市場獲得專利。通過利用該技術將多種雙特異性分子推進臨床，EpimAb 也證明了該新型平台有潛力快速將藥物候選藥物從概念推向開發。關於 EpimAb Biotherapeutics EpimAb Biotherapeutics 是一家臨床階段的生物製藥公司，專門從事多特異性抗體的開發。利用廣泛的內部研究和技術能力，包括專有的 FIT-Ig (Fabs-In-Tandem Immunoglobulin) 和 MAT-Fab (Monovalent Asymmetric Tandem Fab) 雙特異性平台，EpimAb 正在生成並在全球範圍內推進獨特的轉化性臨床前和臨床資產管線，旨在惠及癌症和自身免疫性疾病患者。如需更多資訊，請訪問：www.epimab.com。 EpimAb Biotherapeutics 聯繫方式投資者聯繫Dr. David Gu, CFO直撥：+86-21-61951011IR@epimab.com 業務發展聯繫Dr. Jason Tang, Senior BD Director直撥：+86-21-61951014partnering @epimab.com本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

1 2